Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial.
Eichacker
Peter Q
PQ
Danner
Robert L
RL
Suffredini
Anthony F
AF
Cui
Xizhong
X
Natanson
Charles
C
D000890:Anti-Infective Agents / Q000009:adverse effects* / Q000627:therapeutic use; D017277:Drug Approval; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D011358:Product Surveillance, Postmarketing; D011486:Protein C / Q000009:adverse effects* / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D018805:Sepsis / Q000188:drug therapy*; D014481:United States
D000890:Anti-Infective Agents; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated